On June 2, 2016, Davie, Rebecca Louise; Edwards, Hannah Joy; Evans, David Michael; Hodgson, Simon Teanby published a patent.Application In Synthesis of (2-Bromo-5-methoxyphenyl)methanamine The title of the patent was Preparation of N-((het)arylmethyl)heteroaryl-carboxamides compounds as plasma kallikrein inhibitors. And the patent contained the following:
The invention provides compounds of formula I, compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds Compounds of formula I wherein B is (un)substituted Ph, benzothiophenyl, benzofuranyl, benzomorpholinyl, etc.; W is C and X, Y, Z are independently C, N, O and S; R5 and R6 are independently H, alkyl, NH2, etc.; R7 is H; A is (un)substituted aryl and (un)substituted heteroaryl; are claimed. Example compound II was prepared by amidation of 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid with (3,5-dimethoxyphenyl)methanamine. The invention compounds were evaluated for their plasma kallikrein inhibitory activity (data given). The experimental process involved the reaction of (2-Bromo-5-methoxyphenyl)methanamine(cas: 887581-09-1).Application In Synthesis of (2-Bromo-5-methoxyphenyl)methanamine
The Article related to hetero arylmethyl heteroaryl carboxamide preparation plasma kallikrein inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application In Synthesis of (2-Bromo-5-methoxyphenyl)methanamine
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem